Filing Details
- Accession Number:
- 0001179110-15-000492
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-01-06 16:20:19
- Reporting Period:
- 2015-01-02
- Filing Date:
- 2015-01-06
- Accepted Time:
- 2015-01-06 16:20:19
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
882095 | Gilead Sciences Inc | GILD | Biological Products, (No Disgnostic Substances) (2836) | 943047598 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1190578 | C John Martin | Gilead Sciences, Inc. 333 Lakeside Drive Foster City CA 94404 | Chairman And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-01-02 | 150,000 | $14.50 | 4,272,987 | No | 4 | M | Direct | |
Common Stock | Disposition | 2015-01-02 | 132,200 | $95.01 | 4,140,787 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-01-02 | 17,700 | $95.92 | 4,123,087 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-01-05 | 100 | $96.65 | 4,122,987 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-Qualified Stock option (right to buy) | Disposition | 2015-01-02 | 150,000 | $0.00 | 150,000 | $14.50 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
1,650,000 | 2016-01-25 | No | 4 | M | Direct |
Footnotes
- The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- Sale prices reported for the transactions reported here range from $94.590 to $95.56. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- Sale prices reported for the transactions reported here range from $95.62 to $96.50. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.